MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing Challenges
Bronchopulmonary dysplasia (BPD) remains one of the most devastating consequences of preterm birth resulting in life-long restrictions in lung function. Distorted lung development is caused by its inflammatory response which is mainly provoked by mechanical ventilation, oxygen toxicity and bacterial...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/3/1138 |
| _version_ | 1797407918541242368 |
|---|---|
| author | Maurizio J. Goetz Sarah Kremer Judith Behnke Birte Staude Tayyab Shahzad Lena Holzfurtner Cho-Ming Chao Rory E. Morty Saverio Bellusci Harald Ehrhardt |
| author_facet | Maurizio J. Goetz Sarah Kremer Judith Behnke Birte Staude Tayyab Shahzad Lena Holzfurtner Cho-Ming Chao Rory E. Morty Saverio Bellusci Harald Ehrhardt |
| author_sort | Maurizio J. Goetz |
| collection | DOAJ |
| description | Bronchopulmonary dysplasia (BPD) remains one of the most devastating consequences of preterm birth resulting in life-long restrictions in lung function. Distorted lung development is caused by its inflammatory response which is mainly provoked by mechanical ventilation, oxygen toxicity and bacterial infections. Dysfunction of resident lung mesenchymal stem cells (MSC) represents one key hallmark that drives BPD pathology. Despite all progress in the understanding of pathomechanisms, therapeutics to prevent or treat BPD are to date restricted to a few drugs. The limited therapeutic efficacy of established drugs can be explained by the fact that they fail to concurrently tackle the broad spectrum of disease driving mechanisms and by the huge overlap between distorted signal pathways of lung development and inflammation. The great enthusiasm about MSC based therapies as novel therapeutic for BPD arises from the capacity to inhibit inflammation while simultaneously promoting lung development and repair. Preclinical studies, mainly performed in rodents, raise hopes that there will be finally a broadly acting, efficient therapy at hand to prevent or treat BPD. Our narrative review gives a comprehensive overview on preclinical achievements, results from first early phase clinical studies and challenges to a successful translation into the clinical setting. |
| first_indexed | 2024-03-09T03:49:43Z |
| format | Article |
| id | doaj.art-a5adcc0fbb334395be3a63477e280632 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T03:49:43Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a5adcc0fbb334395be3a63477e2806322023-12-03T14:29:30ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-01-01223113810.3390/ijms22031138MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing ChallengesMaurizio J. Goetz0Sarah Kremer1Judith Behnke2Birte Staude3Tayyab Shahzad4Lena Holzfurtner5Cho-Ming Chao6Rory E. Morty7Saverio Bellusci8Harald Ehrhardt9Department of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyDepartment of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyDepartment of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyDepartment of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyDepartment of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyDepartment of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyDepartment of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyDepartment of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Ludwigstrasse 43, 61231 Bad Nauheim, GermanyDepartment of Internal Medicine II, Universities of Giessen and Marburg Lung Center (UGMLC), Cardiopulmonary Institute (CPI), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Aulweg 130, 35392 Giessen, GermanyDepartment of General Pediatrics and Neonatology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Feulgenstrasse 12, 35392 Giessen, GermanyBronchopulmonary dysplasia (BPD) remains one of the most devastating consequences of preterm birth resulting in life-long restrictions in lung function. Distorted lung development is caused by its inflammatory response which is mainly provoked by mechanical ventilation, oxygen toxicity and bacterial infections. Dysfunction of resident lung mesenchymal stem cells (MSC) represents one key hallmark that drives BPD pathology. Despite all progress in the understanding of pathomechanisms, therapeutics to prevent or treat BPD are to date restricted to a few drugs. The limited therapeutic efficacy of established drugs can be explained by the fact that they fail to concurrently tackle the broad spectrum of disease driving mechanisms and by the huge overlap between distorted signal pathways of lung development and inflammation. The great enthusiasm about MSC based therapies as novel therapeutic for BPD arises from the capacity to inhibit inflammation while simultaneously promoting lung development and repair. Preclinical studies, mainly performed in rodents, raise hopes that there will be finally a broadly acting, efficient therapy at hand to prevent or treat BPD. Our narrative review gives a comprehensive overview on preclinical achievements, results from first early phase clinical studies and challenges to a successful translation into the clinical setting.https://www.mdpi.com/1422-0067/22/3/1138chronic lung diseasebronchopulmonary dysplasiapretermmesenchymal stem cellslung developmentinflammation |
| spellingShingle | Maurizio J. Goetz Sarah Kremer Judith Behnke Birte Staude Tayyab Shahzad Lena Holzfurtner Cho-Ming Chao Rory E. Morty Saverio Bellusci Harald Ehrhardt MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing Challenges International Journal of Molecular Sciences chronic lung disease bronchopulmonary dysplasia preterm mesenchymal stem cells lung development inflammation |
| title | MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing Challenges |
| title_full | MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing Challenges |
| title_fullStr | MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing Challenges |
| title_full_unstemmed | MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing Challenges |
| title_short | MSC Based Therapies to Prevent or Treat BPD—A Narrative Review on Advances and Ongoing Challenges |
| title_sort | msc based therapies to prevent or treat bpd a narrative review on advances and ongoing challenges |
| topic | chronic lung disease bronchopulmonary dysplasia preterm mesenchymal stem cells lung development inflammation |
| url | https://www.mdpi.com/1422-0067/22/3/1138 |
| work_keys_str_mv | AT mauriziojgoetz mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT sarahkremer mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT judithbehnke mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT birtestaude mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT tayyabshahzad mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT lenaholzfurtner mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT chomingchao mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT roryemorty mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT saveriobellusci mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges AT haraldehrhardt mscbasedtherapiestopreventortreatbpdanarrativereviewonadvancesandongoingchallenges |